Investor Relations

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Corporate Profile

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiple TCR-T therapy candidates for the treatment of various solid tumors.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

02 Jun '22
WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management...

Latest Presentations

SEC Filings

Filing date Description Form

A statement of beneficial ownership of common stock by certain persons

SC 13G

A statement of beneficial ownership of common stock by certain persons

SC 13G

A statement of beneficial ownership of common stock by certain persons

SC 13G